EN | UA
EN | UA

Help Support

Back

Efficacy and safety of simvastatin plus narrowband ultraviolet B to treat psoriasis

Efficacy and safety of simvastatin plus narrowband ultraviolet B to treat psoriasis Efficacy and safety of simvastatin plus narrowband ultraviolet B to treat psoriasis
Efficacy and safety of simvastatin plus narrowband ultraviolet B to treat psoriasis Efficacy and safety of simvastatin plus narrowband ultraviolet B to treat psoriasis

A randomized controlled trial determined the efficacy and safety of adding simvastatin to narrowband ultraviolet B (NB-UVB) phototherapy for the management of psoriasis.

See All

Key take away

In patients with psoriasis, oral simvastatin combined with narrowband ultraviolet B phototherapy is not linked with additional beneficial effects. 

Background

A randomized controlled trial determined the efficacy and safety of adding simvastatin to narrowband ultraviolet B (NB-UVB) phototherapy for the management of psoriasis.

Method

This single-center, parallel-group, double-blind, placebo-controlled study recruited 48 people with moderate to severe plaque-type psoriasis who underwent NB-UVB phototherapy. Participants were randomly assigned to receive oral simvastatin [40 mg (two 20 mg tablets together) once a day] or placebo tablet once a day for twelve weeks, together with NB-UVB three times per week for each group. Using Dermatology Life and Quality Index (DLQI) and Psoriasis Area and Severity Index (PASI), an assessment of psoriasis severity was done.

Result

In comparison with the baseline, a considerable decrease in PASI score was noted in both simvastatin and placebo groups after six and twelve weeks. No profound differences in decreasing PASI score and DLQI between the groups were noted at the 6th or 12th week.

Furthermore, DLQI substantially dropped in the placebo group in the 12th week. Contrary to the previous studies, no additional effects were reported for the combination of oral simvastatin and NB-UVB to treat psoriasis. In terms of improvement in quality of life, a non-significant inter-group difference was witnessed.

Conclusion

No substantial differences in PASI and DLQI scores were noted in people receiving NB-UVB phototherapy + simvastatin compared with people receiving NB-UVB phototherapy + placebo.

Source:

Dermatologic Therapy

Article:

Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial

Authors:

Mohammad Al Salman et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: